Lucid Diagnostics Inc
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
LUCD$0.42+4.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenue | $2,428 | $377 |
| Operating expenses: | ||
| Cost of revenue | 5,979 | 3,614 |
| Sales and marketing | 16,404 | 16,134 |
| General and administrative | 19,254 | 23,974 |
| Amortization of acquired intangible assets | 2,021 | 1,649 |
| Research and development | 7,252 | 11,257 |
| Total operating expenses | 50,910 | 56,628 |
| Operating loss | (48,482) | (56,251) |
| Other income (expense): | ||
| Interest income | 424 | 88 |
| Interest expense | (416) | (8) |
| Change in fair value - Senior Secured Convertible Note | (2,980) | — |
| Loss on issue and offering costs - Senior Secured Convertible Note | (1,186) | — |
| Debt extinguishments loss - Senior Secured Convertible Note | (26) | — |
| Other income (expense), net | (4,184) | 80 |
| Loss before provision for income tax | (52,666) | (56,171) |
| Provision for income taxes | — | — |
| Net loss | $(52,666) | $(56,171) |
| Net loss per share - basic and diluted | $(1.26) | $(1.55) |
| Weighted average common shares outstanding, basic and diluted | 41,756,129 | 36,172,421 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.